AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02834546 — intervention group
Intervention type: BIOLOGICAL
Intervention: Sorafenib plasma concentration 4 weeks after treatment initiation
Description: Sorafenib plasma concentrations will be assessed at 4, 8 and 16 weeks by high performance liquid chromatography. The pharmacology Unit of Bordeaux university hospital (Pr Molimard) is a French Center of reference for the dosage of TKI in the plasma
Study NCT02121756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Description: Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
Study NCT02121756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, then Dipyridamole
Description: Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
Study NCT04476199 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Venetoclax and Decitabine
Description: The prognosis of acute myeloid leukemia (AML) patients aged over 60 years is poor and allogeneic stem cell transplantation (allo-SCT) is the only curative option.The association VEN-DEC is a promising combination therapy for AML elderly patients who are fit and eligible for allo-SCT.
Study NCT03122717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: gefitinib is a EGFR inhibitor
Study NCT03122717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor
Study NCT01039194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: galantamine
Description: Capsule, Oral, 8 mg (ER), once daily, Days 1-7
Study NCT01039194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: galantamine
Description: Capsule, Oral, 16 mg (ER), once daily, Days 8-24
Study NCT01039194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsule, Oral, 125 mg, once daily, Days 15-24
Study NCT00932945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Treatment duration: 21 consecutive days
Study NCT01430858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vibration therapy
Description: Galileo 900 platform. Study subjects will be asked to stand on the device for a series of 36 tests, with vibrations applied at various frequencies and amplitudes. A 20-second duration of videomotion \& strain gauge readings will be captured.~Juvent 1000 platform The volunteers will stand on the platform for one minute during which a 20-second duration of videomotion \& strain gauge readings will be captured.~Power Plate Pro5 Two amplitude settings will be tested, described as low \& high. The subject will stand on each platform test for up to 1 minute, during which a 20-second duration of videomotion \& strain gauge readings will be captured.
Study NCT01379014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid Tool
Description: A booklet which outlines to pros and cons of different decision outcomes, and is designed to assist the user in making a decision according to their own specific circumstances
Study NCT01379014 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Treatment as Usual
Description: The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
Study NCT02888808 — intervention group
Intervention type: OTHER
Intervention: Gastroscopy
Description: Upper gastrointestinal endoscopy procedure
Study NCT02006940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: miniprobe Alveoflex
Description: Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
Study NCT02943629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apneic oxygenation: Eight minute
Description: A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
Study NCT02943629 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Without apneic oxygenation
Description: A Pentax AWSTM video laryngoscope with attached P blade will be placed for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
Study NCT02943629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apneic oxygenation: five minutes
Description: A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for five minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
Study NCT02620410 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Axonics Sacral Neuromodulation (SNM) System
Description: The implantable components of the Axonics Sacral Neuromodulation (SNM) System consist of an IPG and tined lead. Additional components include a clinician programmer, surgical tool kit, recharging kit, and patient remote control.
Study NCT00610376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preschool handwashing intervention program
Description: This preschool-based intervention program used a multi-pronged approach that included elements aimed at preschool staff, children, and school nurses, as well as hygienic changes to the classroom environment.
Study NCT00610376 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Preschool handwashing intervention program
Description: This preschool-based intervention program used a multi-pronged approach that included elements aimed at preschool staff, children, and school nurses, as well as hygienic changes to the classroom environment.
Study NCT00610376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home component intervention
Description: The home component was intended to reinforce handwashing practices through education in the home. It consisted of a video, a magnet, and a card.
Study NCT02346851 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Electrical Stimulation (FES) treatment
Description: This study is randomized controlled trial performed by Random permuted blocks. This study has 2 experimental groups and 1 control group. Both experimental group receive FES treatment of their posterior deltoid and supraspinatus. Experimental group 1(Acceleration group) uses Novastim CU FS1 once a day for 30 minutes during 3 weeks. During treatment patient give a maximal effort for shoulder abduction. Experimental group 2 (Convention group) receive cyclic FES treatment for reducing shoulder subluxation. All patients have evaluation pre-intervention, post-intervention, 3 weeks after intervention and 9 weeks after intervention including physical examination and x-ray.
Study NCT02346851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) treatment
Description: This study is randomized controlled trial performed by Random permuted blocks. This study has 2 experimental groups and 1 control group. Both experimental group receive FES treatment of their posterior deltoid and supraspinatus. Experimental group 1(Acceleration group) uses Novastim CU FS1 once a day for 30 minutes during 3 weeks. During treatment patient give a maximal effort for shoulder abduction. Experimental group 2 (Convention group) receive cyclic FES treatment for reducing shoulder subluxation. All patients have evaluation pre-intervention, post-intervention, 3 weeks after intervention and 9 weeks after intervention including physical examination and x-ray.
Study NCT00557193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT00557193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT00557193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT04034745 — intervention group
Intervention type: DRUG
Intervention: telotristat ethyl
Description: 250 mg tablets of Xermelo (telotristat ethyl) is administered orally 3x daily in combination with somatostatin analogs (SSAs) for approximately 84 days as per standard of care
Study NCT02425111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous injection
Study NCT01875744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol 4000
Study NCT01875744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 4000
Study NCT03003845 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: QOL and pain questionnaires will be given to patients at 3, 6, and 12 months post surgery
Study NCT03003845 — intervention group
Intervention type: OTHER
Intervention: Collection of Blood samples
Description: Blood for PBLs will be collected at 3, 6, and 12 months post surgery
Study NCT04352283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preprocedural ultrasound exam of lumbar spine
Description: Preprocedural ultrasound exam of lumbar spine used to determinate needle puncture site
Study NCT03100227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PET [18F] FDG
Description: Measurement of carbohydrate metabolism at the individual level. Standardization of the individual imaging data in a standard anatomical space and then calculation of an average image through the group-level controls.
Study NCT03100227 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: PET [18F] FDG
Description: Measurement of carbohydrate metabolism at the individual level. Standardization of the individual imaging data in a standard anatomical space and then calculation of an average image through the group-level controls.
Study NCT03100227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical MRI
Description: All subjects will benefit from a 3D anatomical MRI to control the normality of their MRI and an automatic segmentation of 73 brain regions by multi-atlas segmentation.
Study NCT03100227 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anatomical MRI
Description: All subjects will benefit from a 3D anatomical MRI to control the normality of their MRI and an automatic segmentation of 73 brain regions by multi-atlas segmentation.
Study NCT04554082 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic sleeve gastrectomy
Description: bariatric surgery to loss weight
Study NCT00477035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIK cells
Description: 2x10e8 cells/kg
Study NCT00477035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 60 mg/kg
Study NCT00477035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bcnu
Description: 15 mg/kg
Study NCT00477035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 100 mg/kg
Study NCT00477035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250 mg/m2
Study NCT00477035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: 30 mg/m2
Study NCT00477035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 200 mg/m2
Study NCT01613274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gum chewing
Description: gum chewing three times a day for up to 20 minutes
Study NCT01613274 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no gum chewing
Description: no gum chewing
Study NCT03264846 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of Serum and Saliva Samples
Description: Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.
Study NCT03414658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: work by interfering with cell division, which leaves the tumor unable to grow and spread
Study NCT03414658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2.
Study NCT03414658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein
Study NCT03414658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Utomilumab is an antibody designed to stimulate the body's immune system to fight cancer cells
Study NCT04135989 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.
Description: Implantation of polymer-free, amphilimus-eluting, drug-eluting stents
Study NCT04135989 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.
Description: Implantation of biodegradable-polymer, everolimus-eluting, drug-eluting stents
Study NCT04135989 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Personalized DAPT duration
Description: Duration of dual antiplatelet therapy according to DAPT score for 3- or 6- months in patients with low DAPT score (stable CAD or ACS, respectively) or for 24-months in patients with high DAPT score
Study NCT04135989 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard DAPT duration
Description: Duration of dual antiplatelet therapy for 12 months.
Study NCT01288326 — intervention group
Intervention type: DRUG
Intervention: liraglutide
Description: Liraglutide will be prescribed and titrated (individually adjusted) by the treating physician.
Study NCT01120418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifloxacin Ophthalmic Suspension 0.6%
Description: administered 3 times a day for 5 days to one eye.
Study NCT04577612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHI-554
Description: hemp-derived CBD in MCT oil
Study NCT04577612 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CHI-554
Description: hemp-derived CBD in MCT oil
Study NCT02561039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.
Study NCT03840486 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-rebreather mask (NRBM)
Description: The non-rebreather mask (NRBM) will be used to assist in the delivery of oxygen. Participants will be placed on NRBM at different flow rates (15 LPM, 35 LPM, or Flush rate at 55 LPM).
Study NCT03840486 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilator mask (NIV)
Description: The NIV is a non-invasive face (nasal) mask for oxygen delivery. Participants will receive oxygen at 50% FiO2 for 3 minutes, 75% FiO2 for 3 minutes or 100% FiO2 for 3 minutes each.
Study NCT03840486 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal cannula EtO2 sensor
Description: The nasal cannula EtO2 sensor will be placed on the participant's face under the mask to detect the EtO2 levels.
Study NCT03840486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen (NRBM)
Description: Oxygen will be delivered via the NRBM. Participants will receive oxygen at different flow rates (15 LPM, 35 LPM, or flush rate at 55 LPM).
Study NCT03840486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen (NIV)
Description: Oxygen will be delivered via the NIV mask. Participants will receive oxygen at 50% FiO2, 75% FiO2 or 100% FiO2 for 3 minutes each.
Study NCT03519737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tPA in combination with the Sonolysis Headframe (TUS)
Description: tPA: 60 minutes per approved labeling TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes
Study NCT03519737 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tPA in combination with the Sonolysis Headframe (Sham TUS)
Description: tPA per approved labeling Sham (inactive) TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes
Study NCT02988817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enapotamab vedotin (HuMax-AXL-ADC)
Description: Enapotamab vedotin (HuMax-AXL-ADC) will be administered intravenously.
Study NCT03082846 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation
Description: The simultaneous integrated boost-intensity modulated technology is adopted to increase both the dose in the surgical cavity and residual tumor (PTV1).The dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1, until dose-limiting toxicity is present,the highest target single dose is 4 Gy/f. The planning target volume (PTV2) including the 2 cm region around surgical cavity and residual tumor remain unchanged, with 2.5 Gy each time and a total of 50 Gy/20f.
Study NCT03082846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide chemotherapy
Description: Temozolomide(TMZ) is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
Study NCT02455752 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LE-TME
Description: Retroperitoneal approach for total mesorectal excision
Study NCT02277288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filled bladder arm
Description: Bladder to be instilled with 200 cc fluid during cystoscopy and no catheter for all mid-urethral sling procedures.
Study NCT00831675 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine 2004-2005 Paediatric Formulation
Description: 0.25 mL (Day 0 and Day 28), Intramuscular
Study NCT02244060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Priming effect from vignette
Description: In the arm of DCV, the self-assessed vision (PSAV) is listed after the vignette questions; however, in the arm of ICV, the self-assessment of vision (SAV) is listed before the vignette questions. Priming effect from vignette will be estimated by comparing those two randomized variables (i.e., SAV and PSAV).
Study NCT02122445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cramer Sports Motion Tape
Description: lower body exercises with and without Cramer Sports Motion tape applied to the hip
Study NCT02867670 — intervention group
Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation
Description: TMS is a form of non-invasive brain stimulation which uses magnetic pulses to stimulate regions of the brain from outside the head, on the scalp. Specifically, TMS is performed with a copper-and-plastic coil that emits a magnetic field, which can affect brain cells in specific locations. In this study, researchers will also use a form of TMS called theta-burst stimulation (TBS), where TMS pulses are delivered rapidly over time.
Study NCT03626558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound measures
Description: It is three diaphragmatic ultrasounds measures of a duration of twenty minutes each approximately. The diaphragmatic ultrasound is practised by trans-thoracic way and is non-invasive, completely painless and does not require the exposure of patients to radiation.
Study NCT04957069 — intervention group
Intervention type: PROCEDURE
Intervention: fixation
Description: double row fixation with 3-4 wire anchors
Study NCT04957069 — intervention group
Intervention type: PROCEDURE
Intervention: primary repair
Description: end-to-end repair
Study NCT05973812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with Bifidobacterium breve PS1
Description: Feeding with an infant formula containing 7 log10 cfu of the strain per gram of formula.
Study NCT05973812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Infant formula NOT supplemented with Bifidobacterium breve PS1
Description: Feeding with the same infant formula but without supplementation with the B. breve strain
Study NCT02167906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arterial stiffness measurement
Study NCT02167906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: arterial stiffness measurement
Study NCT02367924 — intervention group
Intervention type: DRUG
Intervention: trabectedin
Description: The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
Study NCT00710515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: 75mg
Study NCT02282085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Once-Monthly
Study NCT02282085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
Description: Oral antipsychotic medication
Study NCT01816958 — intervention group
Intervention type: OTHER
Intervention: co-administration of TMS and infused ketamine
Description: co-administration of TMS and infused ketamine